Collegium Pharmaceutical, Inc. $COLL Stock Position Trimmed by Renaissance Technologies LLC

Posted by Brian Himes on Jul 28th, 2026

Renaissance Technologies LLC trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 9.1% in the first quarter, HoldingsChannel reports. The firm owned 1,469,449 shares of the specialty pharmaceutical company’s stock after selling 147,900 shares during the period. Renaissance Technologies LLC’s holdings in Collegium Pharmaceutical were worth $48,595,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after buying an additional 825 shares during the last quarter. Millennium Management LLC grew its holdings in Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Collegium Pharmaceutical by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after buying an additional 4,625 shares in the last quarter. Jane Street Group LLC increased its position in Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after acquiring an additional 90,255 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Collegium Pharmaceutical by 3.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock valued at $2,131,000 after acquiring an additional 2,592 shares during the period.

Collegium Pharmaceutical Stock Performance

COLL opened at $35.52 on Tuesday. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 17.41 and a beta of 0.73. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical, Inc. has a 1-year low of $29.19 and a 1-year high of $50.79. The business has a 50 day moving average price of $34.69 and a two-hundred day moving average price of $37.81.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. During the same period last year, the company posted $1.49 EPS. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. Research analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the company. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $57.50.

View Our Latest Stock Report on Collegium Pharmaceutical

About Collegium Pharmaceutical

(Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.